Qualigen Therapeutics, Inc. is announcing an update on patents granted in the first six months of 2025. The patent is Titled “Substitued Naphthalen...
AAVantgarde Bio (AAVantgarde), a clinical-stage biotechnology company developing next-generation gene therapies for inherited retinal diseases, ann...
Strong strategic fit that increases presence in multiple high-growth adjacencies and offers immediate commercial impact from Waters' proven execution...
CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announces a favorable outco...
iFIT, a global leader in connected fitness and interactive content, announced a groundbreaking partnership with Samsung Health, one of the world&rs...
Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, announced that the European Medicines Agency (EMA) will lift the tempo...
The partnership combines Secarna’s OligoCreator® technology with Vect-Horus’ VECTrans® platform to enable system...
Angelini Ventures, the corporate venture firm of Angelini Industries focused on investing in companies developing innovative solutions in BioTech a...
Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today a...
Ofichem Group has signed a definitive agreement to acquire Avivia B.V., a company specialized in formulation development based in Nijmegen, the Netherlan...
Conduit Pharmaceuticals Inc. announces the filing of four new patent applications relating to its key assets AZD1656 and AZD5658, including the Com...
Orchard Therapeutics, a Kyowa Kirin company, announced the last patient has been treated in a registrational trial evaluating the efficacy and safety of ...
PulseSight Therapeutics SAS, an ophthalmology biotech company developing disruptive non-viral vectorized therapies with minimally-invasive delivery techn...
Drug candidate is one of several oncology assets approaching or in clinical development, discovered through Oxford BioTherapeutics’ proprietary OGA...
© 2025 Biopharma Boardroom. All Rights Reserved.
